

Title (en)

USE OF ALDOSE REDUCTASE INHIBITORS TO ENHANCE INSULIN SENSITIVITY IN DIABETES MELLITUS

Publication

EP 0306525 A4 19910424 (EN)

Application

EP 88903550 A 19880318

Priority

US 2851287 A 19870320

Abstract (en)

[origin: WO8806887A1] A method of enhancing insulin sensitivity in mammals (e.g. humans) is described. The method is based on the use of aldose reductase inhibitors to restore and preserve intracellular reduced glutathione levels, thereby enhancing the formation of insulin receptor-mixed disulfide bonds.

IPC 1-7

A61K 31/50; **A61K 31/44**; **A61K 31/42**; **A61K 31/415**; **A61K 31/40**; **A61K 31/195**

IPC 8 full level

A61K 31/195 (2006.01); **A61K 31/40** (2006.01); **A61K 31/415** (2006.01); **A61K 31/42** (2006.01); **A61K 31/44** (2006.01); **A61K 31/50** (2006.01); **A61P 3/08** (2006.01)

CPC (source: EP KR)

A61K 31/195 (2013.01 - EP); **A61K 31/40** (2013.01 - EP); **A61K 31/415** (2013.01 - EP); **A61K 31/42** (2013.01 - EP); **A61K 31/44** (2013.01 - EP); **A61K 31/50** (2013.01 - EP KR); **A61P 3/08** (2017.12 - EP)

Citation (search report)

- US 4609663 A 19860902 - YORK JR BILLIE M [US]
- US 4130714 A 19781219 - SARGES REINHARD
- US 4438272 A 19840320 - YORK JR BILLIE M [US]
- US 4436745 A 19840313 - YORK JR BILLIE M [US]
- US 4864028 A 19890905 - YORK JR BILLIE M [US]
- US 4600717 A 19860715 - YORK JR BILLIE M [US]
- US 4537892 A 19850827 - YORK JR BILLIE M [US]
- Metabolism, Vol. 36, No. 5, May 1987, pages 486-490, Grune & Stratton, Inc.; B. WALKER GRIFFIN et al.: "Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats", whole article.
- Metabolism, Vol. 35, No. 4, suppl. 1, April 1986, pages 83-92, Grune & Stratton, Inc.; J.B. JASPAN et al.: "Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes", Abstract.
- Pharmacology, Vol. 32, 1986, pages 52-60; A. BEYER-MEARS et al.: "Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor", Abstract.
- Biochimica et Biophysica Acta, Vol. 870, 1986, pages 302-311, Elsevier Science Publishers B.V. (Biomedical Division); S.K. SRIVASTAVA et al.: "Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties", Abstract.
- CHEMICAL ABSTRACTS, Vol. 105, No. 11, 15th September 1986, page 337, Abstract No. 102604d, Columbus, Ohio, US; & JP,A,61 078 725 (AMERICAN HOME PRODUCTS CORP.) 22-04-1986, whole Abstract.
- Metabolism, Vol. 34, No. 10, October 1985, pages 885-892, Grune & Stratton, Inc.; N. SIMARD-DUQUESNE et al.: "The effects of a new aldose reductase inhibitor (Tolrestat) in galactosemic and diabetic rats", whole article.
- Metabolism, Vol. 34, No. 4, April 1985, pages 336-344, Grune & Stratton, Inc.; D. STRIBLING et al.: "Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat", Abstract.
- Chem. Pharm. Bull., Vol. 32, No. 5, 1984, pages 2030-2032; I. MIWA et al.: "Hypoglycemic activity of aldose reductase inhibitor, 1 (p-bromophenyl) sulfonyl hydantoin", whole article.
- Horm. Metab. Res., Vol. 10, 1978, pages 280-282, Georg Thieme Publishers; W. LIPPMANN et al.: "Effect of alrestatin on arginine-induced secretion of glycagon and insulin in the rat", Summary.
- Exp. Eye Res., Vol. 46, 1988, pages 517-530, Academic Press Ltd; M.F. LOU et al.: "Glutathione depletion in the lens of galactosemic and diabetic rats", whole article.
- See references of WO 8806887A1

Designated contracting state (EPC)

AT BE CH DE FR GB IT LI LU NL SE

DOCDB simple family (publication)

WO 8806887 A1 19880922; AU 1549088 A 19881010; AU 598366 B2 19900621; CA 1310269 C 19921117; EP 0306525 A1 19890315; EP 0306525 A4 19910424; JP H01503460 A 19891122; KR 890700346 A 19890424

DOCDB simple family (application)

US 8800814 W 19880318; AU 1549088 A 19880318; CA 561908 A 19880318; EP 88903550 A 19880318; JP 50319088 A 19880318; KR 880701502 A 19881119